Trials / Completed
CompletedNCT04736147
A Study of JNJ-64300535 in Healthy Participants
A Phase 1 Open-label Study to Assess the Immunogenicity, Safety, and Reactogenicity of JNJ-64300535, a DNA Vaccine Administered by Electroporation-mediated Intramuscular Injection, in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the cellular immunogenicity of 3 monthly electroporation-mediated intramuscular (IM) injections of JNJ-64300535 in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | JNJ-64300535 | JNJ-64300535 injection will be administered intramuscularly. |
Timeline
- Start date
- 2021-02-03
- Primary completion
- 2021-12-07
- Completion
- 2021-12-07
- First posted
- 2021-02-03
- Last updated
- 2021-12-22
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT04736147. Inclusion in this directory is not an endorsement.